{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:25:47Z","timestamp":1791325547908,"version":"4.3.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Janssen Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004329","name":"Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["2016-1103"],"award-info":[{"award-number":["2016-1103"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["32774"],"award-info":[{"award-number":["32774"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010156","name":"Netherlands Leprosy Relief","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.euo.2019.01.009","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T23:43:33Z","timestamp":1548891813000},"page":"298-305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study"],"prefix":"10.1016","volume":"3","author":[{"given":"Thomas","family":"Loubersac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moli\u00e8re","family":"Nguile-Makao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Pouliot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Fradet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Toren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2019.01.009_bib0140","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2019.01.009_bib0145","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/aja.2013.38","article-title":"Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer","volume":"15","author":"Toren","year":"2013","journal-title":"Asian J Androl"},{"key":"10.1016\/j.euo.2019.01.009_bib0150","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.euf.2016.12.006","article-title":"The natural history and outcome predictors of metastatic castration-resistant prostate cancer","volume":"2","author":"van Soest","year":"2016","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2019.01.009_bib0155","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.euo.2018.02.009","article-title":"Consensus statement on circulating biomarkers for advanced prostate cancer","volume":"1","author":"Sumanasuriya","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2019.01.009_bib0160","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.euo.2019.01.009_bib0165","doi-asserted-by":"crossref","first-page":"e0158770","DOI":"10.1371\/journal.pone.0158770","article-title":"Neutrophil-to-lymphocyte ratio predicts PSA response and prognosis in prostate cancer: a systematic review and meta-analysis","volume":"11","author":"Cao","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.euo.2019.01.009_bib0170","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/annonc\/mdu569","article-title":"Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials","volume":"26","author":"van Soest","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2019.01.009_bib0175","doi-asserted-by":"crossref","first-page":"e0158952","DOI":"10.1371\/journal.pone.0158952","article-title":"Persistent neutrophil to lymphocyte ratio >3 during treatment with enzalutamide and clinical outcome in patients with castration-resistant prostate cancer","volume":"11","author":"Conteduca","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.euo.2019.01.009_bib0180","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.clgc.2014.03.005","article-title":"Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer","volume":"12","author":"Sonpavde","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2019.01.009_bib0185","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3389\/fphar.2016.00376","article-title":"Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone","volume":"7","author":"Lolli","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.euo.2019.01.009_bib0190","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2019.01.009_bib0195","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.eururo.2014.02.056","article-title":"Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)","volume":"66","author":"Rathkopf","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2019.01.009_bib0200","doi-asserted-by":"crossref","first-page":"E383","DOI":"10.5489\/cuaj.3550","article-title":"Role of neutrophil-to-lymphocyte ratio in prediction of Gleason score upgrading and disease upstaging in low-risk prostate cancer patients eligible for active surveillance","volume":"10","author":"Gokce","year":"2016","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.euo.2019.01.009_bib0205","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1093\/annonc\/mdy406","article-title":"Development and validation of a prognostic model for overall survival in chemotherapy-na\u00efve men with metastatic castration-resistant prostate cancer","volume":"29","author":"Armstrong","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2019.01.009_bib0210","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2019.01.009_bib0215","doi-asserted-by":"crossref","first-page":"22089","DOI":"10.1038\/srep22089","article-title":"Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients","volume":"6","author":"Gu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.euo.2019.01.009_bib0220","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1093\/annonc\/mdu587","article-title":"Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use","volume":"26","author":"Lorente","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2019.01.009_bib0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2017.05.012","article-title":"Neutrophil to lymphocyte ratio in castration-resistant prostate cancer patients treated with daily oral corticosteroids","volume":"15","author":"Mehra","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2019.01.009_bib0230","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2019.01.009_bib0235","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2019.01.009_bib0240","first-page":"592","article-title":"Baseline neutrophil-to-lymphocyte ratio predicts the prognosis of castration-resistant prostate cancer treated with abiraterone acetate","volume":"8","author":"Yasui","year":"2018","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.euo.2019.01.009_bib0245","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/annonc\/mdt581","article-title":"Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer","volume":"25","author":"Leibowitz-Amit","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2019.01.009_bib0250","doi-asserted-by":"crossref","DOI":"10.1177\/2054270415611332","article-title":"Neutrophil-lymphocyte ratio is prognostic but not predictive of response to abiraterone in metastatic castration-resistant prostate cancer","volume":"6","author":"Sundar","year":"2015","journal-title":"JRSM Open"},{"key":"10.1016\/j.euo.2019.01.009_bib0255","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s12094-017-1699-x","article-title":"Platelet-lymphocyte and neutrophil-lymphocyte ratios are prognostic but not predictive of response to abiraterone acetate in metastatic castration-resistant prostate cancer","volume":"19","author":"Lozano Mart\u00ednez","year":"2017","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.euo.2019.01.009_bib0260","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12885-016-2134-3","article-title":"Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer","volume":"16","author":"Kawahara","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euo.2019.01.009_bib0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2017.07.014","article-title":"Prognostic index model for progression-free survival in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer treated with abiraterone acetate plus prednisone","volume":"16","author":"Ryan","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2019.01.009_bib0270","doi-asserted-by":"crossref","first-page":"7538647","DOI":"10.1155\/2017\/7538647","article-title":"Neutrophil-to-lymphocyte ratio predicts prognosis in castration-resistant prostate cancer patients who received cabazitaxel chemotherapy","volume":"2017","author":"Uemura","year":"2017","journal-title":"Biomed Res Int"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931119300100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931119300100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:45:56Z","timestamp":1762875956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931119300100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S2588931119300100"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2019.01.009","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2019.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}